Shahin Lockman1. 1. Harvard Medical School, Brigham and Women's Hospital, Harvard School of Public Health, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: HIV-1 drug resistance can emerge in both maternal and infant virus after exposure to antiretroviral drugs for the prevention of mother-to-child transmission of HIV. The purpose of this review is to discuss the prevalence and clinical implications (for antiretroviral treatment outcomes) of this drug resistance, focusing on more recent information. RECENT FINDINGS: New, highly sensitive laboratory assays have been developed that demonstrate even greater than previously known levels of drug resistance in minor HIV-1 variants after the use of single-dose nevirapine. At the same time, new data related to virological and immunological outcomes among women and infants after exposure to short-course prevention of mother-to-child transmission regimens suggest that although the response to nevirapine-based antiretroviral therapy after single-dose nevirapine may be compromised, this is less of a problem among women starting antiretroviral therapy more remotely from nevirapine exposure. SUMMARY: Whereas single-dose nevirapine alone should be reserved for settings in which other combination antiretroviral interventions are not feasible for the prevention of mother-to-child transmission, recent data provide measured reassurance to women regarding their future response to nevirapine-containing antiretroviral therapy.
PURPOSE OF REVIEW: HIV-1 drug resistance can emerge in both maternal and infant virus after exposure to antiretroviral drugs for the prevention of mother-to-child transmission of HIV. The purpose of this review is to discuss the prevalence and clinical implications (for antiretroviral treatment outcomes) of this drug resistance, focusing on more recent information. RECENT FINDINGS: New, highly sensitive laboratory assays have been developed that demonstrate even greater than previously known levels of drug resistance in minor HIV-1 variants after the use of single-dose nevirapine. At the same time, new data related to virological and immunological outcomes among women and infants after exposure to short-course prevention of mother-to-child transmission regimens suggest that although the response to nevirapine-based antiretroviral therapy after single-dose nevirapine may be compromised, this is less of a problem among women starting antiretroviral therapy more remotely from nevirapine exposure. SUMMARY: Whereas single-dose nevirapine alone should be reserved for settings in which other combination antiretroviral interventions are not feasible for the prevention of mother-to-child transmission, recent data provide measured reassurance to women regarding their future response to nevirapine-containing antiretroviral therapy.
Authors: William I Towler; Linda Barlow-Mosha; Jessica D Church; Danstan Bagenda; Patrick Ajuna; Micheal Mubiru; Philippa Musoke; Susan H Eshleman Journal: AIDS Res Hum Retroviruses Date: 2010-05 Impact factor: 2.205
Authors: Dara A Lehman; Jared M Baeten; Connor O McCoy; Julie F Weis; Dylan Peterson; Gerald Mbara; Deborah Donnell; Katherine K Thomas; Craig W Hendrix; Mark A Marzinke; Lisa Frenkel; Patrick Ndase; Nelly R Mugo; Connie Celum; Julie Overbaugh; Frederick A Matsen Journal: J Infect Dis Date: 2015-01-13 Impact factor: 5.226
Authors: Ziad El-Khatib; Allison K Delong; David Katzenstein; Anna Mia Ekstrom; Johanna Ledwaba; Lerato Mohapi; Fatima Laher; Max Petzold; Lynn Morris; Rami Kantor Journal: J AIDS Clin Res Date: 2011-02-18